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Abstract
Studying the genetic diversity and natural polymorphisms of HIV-1 would benefit our 
understanding of HIV drug resistance (HIVDR) development and predict treatment outcomes. In 
this study, we have characterized the HIV-1 genetic diversity and natural polymorphisms at the 5′ 
region of the pol gene encompassing the protease (PR) and reverse transcriptase (RT) from 271 
plasma specimens collected in 2008 from HIV-1-infected patients who were eligible for initiating 
antiretroviral therapy in Abuja (Nigeria). The analysis indicated that the predominant subtype was 
subtype G (31.0%), followed by CRF02-AG (19.2 %), CRF43-02G (18.5%), and A/CRF36-cpx 
(11.4%); the remaining (19.9%) were other subtypes and circulating (CRF) and unique (URF) 
recombinant forms. Recombinant viruses (68.6%) were the major viral strains in the region. 
Eighty-four subtype G sequences were further mainly classified into two major and two minor 
clusters; sequences in the two major clusters were closely related to the HIV-1 strains in two of the 
three major subtype G clusters detected worldwide. Those in the two minor clusters appear to be 
new subtype G strains circulating only in Abuja. The pretreatment DR prevalence was < 3%; 
however, numerous natural polymorphisms were present. Eleven polymorphic mutations (G16E, 
K20I, L23P, E35D, M36I, N37D/S/T, R57K, L63P, and V82I) were detected in the PR that were 
subtype or CRF specific while only three mutations (D123N, I135T, and I135V) were identified in 
the RT. Overall, this study indicates an evolving HIV-1 epidemic in Abuja with recombinant 
viruses becoming the dominant strains and the emergence of new subtype G strains; pretreatment 
HIVDR was low and the occurrence of natural polymorphism in the PR region was subtype or 
CRF dependent.
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ONE OF THE MAJOR CHALLENGES in controlling the HIV/AIDS pandemic is the 
genetic variability of HIV and its consequences for the development of antiretroviral (ARV) 
drugs and vaccine. HIV vaccine development has been hindered by its extensive genetic 
heterogeneity.1,2 Currently, the genetic diversity of HIV-1 in the worldwide epidemic is 
characterized by four groups, M, N, O, and P.3 The group M is the leading cause of the 
global epidemics and is composed of nine subtypes (A,B, C, D, F, G, H, J, and K),3 more 
than 49 circulating recombinant forms (CRFs), and 100 unique recombinant forms 
(URFs).4–6 While subtype B is the predominant strain in the developed countries, the non-B 
subtypes as well as CRFs and URFs are the major epidemic strains characterized in the 
African region.7–30 In sub-Saharan Africa, multiple HIV-1 subtypes are found along with 
various CRFs such as CRF01-AE in Central Africa and CRF02-AG in West 
Africa.7,9,15,16,31–37
In Nigeria, studies have shown a diversified HIV-1 epidemic with the viral subtype G, 
CRF06-cpx, CRF02-AG, sub-subtype A3, and other recombinants 
cocirculating.16,18,34,38–40 In a study published in 2000, subtype A was predominant (about 
70%) in the southwest-Lagos state and subtype G was predominant in the northwest-Kano 
state (about 58%), while both subtypes A (49%) and G (47%) were observed to be equally 
distributed in the northeast (Maiduguri).18 In 2006, a study in Oyo state (southeast) showed 
the predominance of CRF02-AG (57%), subtype G (26%), and CRF06-cpx (11%),16 and 
similar results with 39–45% for CRF02-AG and 38% for subtype G were reported in 200941 
and 2012.39
Characterization of the polymorphisms within the protease (PR) and reverse transcriptase 
(RT) genes have been conducted mostly for subtype B viruses; few studies have been 
conducted for non-B subtype viruses, and their impact on highly active antiretroviral therapy 
(HAART) is undetermined.9,29,42–46 Indeed, it has been shown that differences in codon 
sequences at positions associated with drug resistance mutations (DRMs) might predispose 
viral isolates of different subtypes to encode different amino acid substitutions that can 
affect the rate of emergence of resistance, cross-resistance to same-class drugs, and 
potentially drug susceptibility and clinical outcomes.8,47 Data from virological and 
biochemical analysis revealed that natural variations in amino acids can affect the degree of 
drug resistance (DR) conferred by some mutations.48 It has been shown that HIV-2 and 
group O HIV-1 viruses are naturally resistant to nonnucleoside RT inhibitors (NNRTIs) due 
to mutations present in their RT gene.49,50 Moreover, differences in nucleotide and 
mutational motifs (these are transitions and transversions needed to develop DR to different 
antivirals) between subtypes can affect the genetic barrier for resistance.51,52
One good example of this is the V106M polymorphism in the RT of subtype C viruses 
inducing resistance to NNRTIs.53 However, study of the influence of genetic variability and 
polymorphisms on HIV-1 DR development in places where diverse HIV-1 non-B subtypes, 
CRFs, and URFs are co-circulating is limited. We undertook this study in Abuja, Nigeria’s 
capital city, using specimens collected from HIV-1-infected patients who were eligible for 
initiation of ART at two treatment sites. The aims of this analysis were to (1) determine the 
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HIV-1 subtype distribution in the cohort; (2) identify and characterize baseline 
polymorphisms and DRMs at pretreatment and the association of any specific mutational 
pattern with HIV-1 subtypes or CRFs; and (3) evaluate the potential impact of these 
polymorphisms on DR development.
Materials and Methods
Specimens
Patients were recruited for a prospective cohort study to monitor HIVDR development. The 
median age was 34 years [interquartile range (IQR), 28–40 years]; 38% were male, while 
62% were female at the time of ART initiation. The median CD4 count was 149 cells/μl 
(IQR, 73–205 cells/μl) and 72% of participants had a CD4 count of ≤200 cells/μl. Detailed 
demographic and clinical data of this cohort were described previously.54 The specimens 
were collected from HIV-infected patients initiating ART from two sites in Abuja, between 
January and July 2008. Samples were systematically collected from all the patients who 
were eligible for ART to limit the introduction of bias in the nature and quantity of 
polymorphisms and/or DRMs detected.
RT-PCR and DNA sequencing
Sequences were generated from these plasma specimens using the broadly sensitive HIV-1 
genotyping assay that amplifies the 5′ region of the HIV-1 pol gene including DR mutation 
sites in the PR and RT regions.55 Sequences were edited with the ReCall program56 and the 
consensus sequences were made for further analysis.
HIV-1 subtype determination and characterization
HIV-1 subtypes and CRFs for the newly obtained 271 sequences were initially determined 
by phylogenetic analysis using MEGA 557 along with 109 reference sequences including 
subtypes A to K and all available CRFs, downloaded from the Los Alamos HIV sequence 
database (2010 version, www.hiv.lanl.gov/). Neighbor-joining and maximum likelihood 
with algorithms of Tamura-Nei were used for the analysis with 1,000 bootstrap replicates. 
The bootstrap values above 70% were considered significant.58 For the sequences whose 
HIV-1 subtypes or CRFs could not be determined by the initial phylogenetic analysis, 
pairwise genetic distances (MEGA57), similarity, and bootscan analysis (SimPlot, v.3.5159) 
were performed for gene structure (recombination) analysis. If a segment of the query 
sequences with a length of < 200 nucleotides had a similarity of < 95% to the reference 
sequences, a U was assigned to indicate an unclassifiable segment within a sequence; the 
relatedness of these unclassifiable sequences to any sequence in the public database was 
then determined by using a standard GenBank Blast search. If the similarity scores were < 
95%, the sequences were considered not closely related.
The phylogeny of 84 subtype G sequences identified from the initial subtyping was further 
assessed by using the MrBayes tool (Geneious, v.6.1.8, Biomatters Ltd., San Francisco, CA) 
with the references of subtype G (n = 36) and other major HIV-1 subtypes (n = 21) 
downloaded from the Los Alamos HIV sequence database (www.hiv.lanl.gov/). The 
posterior probabilities of trees were estimated using Markov chain Monte Carlo (MCMC) 
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approach with a chain length of 1,100,000 and an HKY85 substitution model.60 Only 
probability values > 70% at the nodes of major clusters were presented in the tree.
Identification of major drug resistance-associated mutations and natural polymorphisms
Major HIVDR mutations of the 271 quality-assured sequences were identified by the 
Calibrated Population Resistance Tool (CPR), version 6.0, deployed at the Stanford HIV 
drug resistance website (http://cpr.stanford.edu/cpr.cgi). Sequences were aligned using 
Clustal W (BioEdit version 7.0.9.1, Carlsbad, CA) and were visually compared across 
subtypes to identify both synonymous and nonsynonymous substitutions at polymorphic 
and/or DR sites in both RT and PR genes, which also allowed us to determine any subtype-
specific mutational pattern or motif. The mutational motif is defined as the number of 
transitions or transversions needed to develop resistance to different classes of ARVs.51,52 
The specific mutational pattern analysis was focused on the sites that are polymorphic 
and/or involved in HIVDR development to any drug class of ARVs.
Results
HIV-1 subtype distribution
Phylogenetic analyses of the 271 newly obtained nucleotide sequences along with 109 
HIV-1 subtype and CRF reference sequences revealed that 93.7% (254/271) of the 
sequences could be subtyped with our sequence analysis procedures while 6.3% (17/271) 
could not be assigned a standard subtype or CRF, which were denoted as unclassifiable 
sequences (Table 1). A total of 16 possible types of HIV-1 strains were identified. The 
predominant strains were subtype G (31.0%), CRF02-AG (19.2%), and CRF43-02G 
(18.5%), accounting for 68.7% of the total sequences analyzed. The remaining strains 
(31.3%) were A/CRF36-cpx (11.4%), CRF06-cpx (5.5%), CRF25-cpx (3.3%), CRF36-cpx 
(2.2%), A/CRF02-AG (1.5%), CRF15-01B/G (0.4%), CRF43-02G/G (0.4%), and 
unclassifiable (6.3%). Overall, the recombinant viral strains, including CRFs and URFs, 
accounted for 68.6%, while pure subtypes (G and C) were only 31.4%.
It is interesting to note that the subtype G sequences identified in this study (n = 84) 
exhibited intrasubtype diversity by segregating into two large distinct clusters in the initial 
phylogenetic analysis (data not shown). To further understand the diversity of these G 
sequences, we analyzed them with all available subtype G reference sequences from the Los 
Alamos database. Results indicated that the G sequences mainly formed three major and two 
minor clusters (Fig. 1). For description purpose, we named them G1-3 and Gm1-2, 
respectively. Most of the G sequences from this study (n = 64) fell into two of the three 
known major subtype G clusters, G1 (n = 19) and G3 (n = 45), and only one clustered in the 
G2 along with reference sequences from other countries. Interestingly, the remaining study 
sequences formed two independent minor clusters of Gm1 and Gm2 without clustering with 
any sequence from other countries with an exception of two sequences that didn’t group into 
clusters.
For those 17 sequences that a subtype/CRF could not be assigned, 13 representatives were 
selected for further analyses. Genetic distance analysis showed that they were not closely 
Diallo et al. Page 4













related to any subtype reference sequences, but had approximately equal distances to two or 
multiple subtype sequences (Table 2). Sequence similarity analysis indicated that they had 
complicated gene structures with multiple subtypes involved (Fig. 2a). Bootscan analysis 
further revealed that eight of them had strong evidence of recombination between multiple 
subtypes (Fig. 2b). Blast search for closely related sequences in the GenBank database 
showed the highest similarity hits were 93–95% to the GenBank sequences (data not 
shown), indicating they might be new recombinant viruses.
HIV-1 drug resistance-associated mutations
Among the 271 sequences analyzed, 28% (76/271) had polymorphisms and/or primary 
and/or accessory DRMs in the PR and RT region (Table 3). The CPR analysis identified the 
PI mutations M46L, I85V, and F53Y as well as the NRTI mutations M41L and V75M, and 
the NNRTI mutations K101E, K103N, and G190A as Surveillance Drug Resistance 
Mutations (SDRM).61,62 The total number of detected mutations in the PR was 11, 
distributed at 9 sites among 11 samples. In the RT, 81 mutations were identified and 
distributed at 15 sites among 69 samples. Seven specimens had PI mutations but no NRTI or 
NNRTI mutations, while the remaining 69 specimens with resistance-associated mutations 
had no PI mutations.
In the PR region, one sample displayed the K43T mutation; another one had the M46L, 
while a third specimen had K53Y, A71V, and I85V. The T74S mutation was found in the 
PR of six specimens.
We also detected NRTI selected mutations M41L, E44D, T69ANS, V75M, and V118I, and 
NNRTI mutations V90I, A98G, K101EQ, K103NR, V106I, V108I, E138A, V179EI, and 
G190A (Table 3). Due to the M41L mutation detected in one specimen, the virus would 
have reduced susceptibility to zidovudine (AZT) and stavudine (d4T). Five specimens had 
A98G, K101EK, V108IV, K103N, E138A, and G190A occurring alone or in combination 
with each other, which could cause intermediate and/or high-level resistance to delavirdine 
(DLV), efavirenz (EFV), etravirine (ETR), and nevirapine (NVP). The mutation E138A 
associated with a decreased response to ETR, the second generation NNRTI, was found in 
16% (12/76) of the specimens displaying DR mutations. There were only three specimens 
that had DR mutations associated with two combined drug classes (NRTIs plus NNRTIs). 
The overall resistance rate within the cohort was < 3% and the affected drugs were one PI 
[nelfinavir, (NFV)], two NRTIs (AZT and d4T), and five NNRTIs [EFV, DLV, ETR, 
rilpivirine (RPV), and NVP].
Among all the mutations detected, T74S (54.5%) in PR and E138A (17%), V179I (16%), 
followed by V118I and V179E (14% each) in RT were the most prevalent, while T69NS, 
V90I, and V106I were present at only 5% each. Within the cohort, the rate of these 
mutations was 2.2% for T74S, 4% for V118I and V179E each, 4.5% for V179I, and 5% for 
E138A. The prevalence for T69NS, V90I, and V106I was 1.5%, respectively. L89T/I, the 
nonpolymorphic PI-selected mutation of uncertain phenotypic and clinical significance was 
also detected.
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Of the 271 sequences analyzed, 11 polymorphic mutations (G16E, K20I, L23P, E35D, 
M36I, N37D/S/T, R57K, L63P, and V82I) in the PR and 3 (D123N and I135T/V) in the RT 
were identified. According to the Stanford DR algorithm, these substitutions occurred in the 
wild type (WT) of non-B subtype viruses and have no effect on DR for PIs or RTIs; 
however, when combined with other mutations, they increase the resistance to PIs or RTIs in 
subtype B viruses.
Uncommon mutations
Numerous uncommon mutations with unknown impact and/or function within the PR and 
the RT were identified. In PR, 58 uncommon mutations were detected at 28 positions, while 
in RT the number was 96 at 58 positions. Some of these mutations occurred at a very high 
rate and were subtype specific in the PR gene. For example, the E35Q mutation occurred in 
67% of all subtype G sequences and in only 5% of CRF02-AG sequences, but was absent in 
all other subtypes and CRFs. E35K occurred in 5% of CRF02-AG but was absent in the rest 
of the other subtypes. However, in the RT gene, we did not detect a high prevalence of an 
uncommon mutation or subtype-specific mutational pattern. The random mutation rates 
ranged from 0.5% to 15%.
Synonymy and subtype-specific codon mutational pattern
We next performed a codon-by-codon comparison of the nucleotide sequences of subtype B 
(HXB2) to the sequences in the cohort to detect any subtype-specific mutational patterns 
(Table 4). We found that at position 179 of the RT gene, all sequences of CRF06-cpx (6/6), 
subtype G (2/2), and CRF43-02G (2/2) harbored the V179E mutation, while all sequences of 
CRF36-cpx (1/1), A/CRF02-AG (2/2), CRF36-cpx/B (2/2), A/CRF15-01B (4/4), and 
CRF25-cpx (2/2) had the V179I mutation. The WT CRF06-cpx and subtype G mainly had a 
codon GTG at position 179, while the WT of the other subtypes and CRFs possessed the 
GTT at this position except for CRF36-cpx, which had a codon ATA.
Discussion
We have analyzed the PR and RT regions of the pol gene of 271 sequences generated from 
plasma specimens collected from ART-naive HIV-1-infected patients initiating ART in 
Abuja, Nigeria in 2008. Phylogenetic analysis revealed that recombinant viruses have 
become the dominant strains over pure subtypes. The subtype G viruses have further 
diversified into three major subtype G clusters using worldwide sequences, and most 
Nigerian sequences from this study were closely related to two of the three clusters (Fig. 1, 
G1 and G3), indicating a close epidemiological relationship of HIV epidemics between 
Nigeria and countries in Europe, West Africa, and Asia during the periods of 1992–2004 
(G1) and 2000–2009 (G3), respectively. We also noticed that the HIV-1 strains in the G2 
cluster formed by sequences obtained from countries in Europe, East and West Africa, and 
South America from 1993 to 2009 had a minimal impact to the HIV epidemic in Nigeria, 
and strains in the two minor clusters, Gm1 and Gm2, appear to be indigenous viruses that 
had no relationship to the HIV subtype G strains circulating in other countries.
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The three major subtype G clusters were reported previously as GWA-I, GWA-II, and 
GCA6,22,63 However, within a G cluster, different strains may be present. For example, in the 
G3 cluster, there are possibly four different strains, denoted as G3A–D (Fig. 1), while strain 
G3C and G3D seem to circulate only in Nigeria. Studies have suggested that subtype G 
emerged in Central Africa in 1968 (1956–1976), and between the middle and late 1970s two 
subtype G strains were probably introduced into Nigeria.63 Since then, they were 
disseminated locally and to neighboring countries, leading to the origin of two major 
western African clades (GWA-I and GWA-II). For the strains in the two minor clusters of 
Gm1 and Gm2, we have not identified any phylogenetic relationship of these strains to those 
from other countries (> 95% similarity) or to those detected in other regions of the country 
(data not shown), indicating that they might be newly emerging and locally circulating only 
in the Abuja area.
We also observed an evolved subtype distribution in the country. Prior to 2000, subtypes A 
(61%) and G (31%) were dominant in the south and north, respectively, and CRF02-AG was 
not detected in the country.18 However, after 2000, studies revealed that the prevalence of 
subtype A was greatly reduced with a slight reduction of subtype G and a remarkable 
increase of CRF02-AG (39–57%).16,34,38–41 In this study, we did not detect pure subtype A 
and had rates for subtype G (31.0%) and CRF02-AG (19.2%) detected in the capital area of 
Abuja similar to those detected in other areas, which is in agreement with the subtype 
distribution patterns reported in the country.16,34,38,39 Our data and other studies suggest 
that among the two previously dominant subtypes, one (subtype A) is disappearing and the 
other (subtype G) is still playing an important role but is circulating at different rates in the 
country. Meanwhile the progeny (CRF02-AG) of subtypes A and G are emerging quickly in 
the HIV epidemic in the country. In addition, CRF43-02G is becoming one of the dominant 
subtypes in Abuja, which was not reported in other areas of the country. Nevertheless, the 
majority of the current circulating HIV strains were derived from the subtypes or 
recombinant forms between subtypes A and G, again indicating localized transmission and 
circulation.
The overall pretreatment HIVDR rate in the cohort was less than 3%, which is expected due 
to the short time of ART implementation in the country at the time of the study. This rate is 
in agreement with the rates reported in Jos, in the Plateau State,40 and the North Central 
region of Nigeria. In the protease region, one sample displayed the K43T mutation, which 
was associated with a decreased virological response to tipranavir boosted with ritonavir 
(TPV/r) in the RESIST trials.64 One sample harbored the M46L mutation, which is a 
primary mutation inducing an intermediate level of resistance to NFV. A rare treatment-
associated mutation K53Y, the polymorphic mutation A71V, as well as the PI-selected 
mutation I85V were also found in one sample each. Six specimens had the T74S mutation 
that induces a potential low level of resistance [classified as sensitive per the World Health 
Organization (WHO) interpretation]65 to PIs.
We also identified subtype/CRF-specific mutation patterns in the PR and RT gene regions. 
For instance, K20I in the PR region was present in all subtypes and CRFs except for eight 
sequences that were all subtype A-containing recombinants.34 The polymorphic mutations 
M36I, L63P, V82I, and M89I were proportionately present in the sequences of CRF02-AG, 
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CRF43-02G, and CRF06-cpx and subtype G. A study has shown that the polymorphic 
mutation M36I in the PR region was associated with a higher rate of PI treatment failure.66 
Furthermore, biochemical studies of this mutation with subtypes A and C recombinant I36 
PR revealed that the PR enzymes of non-subtype B viruses have a higher inhibition constant 
(Ki) and a greater catalytic efficiency than subtype B viruses67 and that introduction of I36 
into subtype B HIV-1 resulted in a higher virus replication capacity in both the absence and 
presence of PIs.7 In addition, we found that mutations E35D, N37DST, R57K, and K70R in 
the PR and D123N and I135TV in the RT were present at high rates in this cohort. These 
mutations have been shown to be associated with increased or decreased DR to some 
ARVs.68–70 Several other mutations observed in this study were not classically associated 
with resistance and their biological functionality remains to be elucidated. Since some of the 
uncommon mutations occurred at a very high frequency in a subtype/CRF-specific manner, 
they may warrant further investigation to determine their biological functions within the 
virus genome.
The analysis of the mutational pattern suggests that the V179I mutation in the RT is not only 
the preferred mutation in subtype B viruses, but also occurs in non-B subtypes and CRFs. 
Subtype G, CRF43-02G, and CRF06-cpx viruses utilized the codon GTG/GTA to encode 
valine and more likely to develop V179E mutations,16,34,38,39,71 whereas other CRF viruses 
are biased toward V179I and V179D. This pattern of amino acid substitution by a single 
nucleotide change is called quasisynonymy; it may explain the high rate of the V179E found 
in subtype G and CRF06-cpx in this cohort and is concordant with published data and 
statistics predicting the occurrence of this mutation at RT position 179 of these 
viruses.16,71,72
In summary, this study has shown an evolving HIV-1 epidemic in Abuja, with recombinant 
viruses becoming the prevailing strains and locally circulating strains emerging. This 
evolving trend in the HIV-1 epidemic deserves closer monitoring since a recent study has 
shown that a recombinant HIV-1 sub-subtype A3 and CRF02-AG virus was more virulent 
than the original viral strains.73 In addition, it has also confirmed that the occurrence of DR 
may be influenced by quasisynonymy and the genetic cost of mutations.
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Phylogenetic analysis of subtype G sequences with HIV-1 reference sequences. The tree was 
constructed with 84 newly characterized Nigerian subtype G sequences and 57 reference 
sequences downloaded from the Los Alamos HIV database (www.hiv.lanl.gov/) 
representing major subtypes (n = 21) of A, B, C, D, F, H, K, and G (n = 36). Only the names 
of reference sequences were given in the tree. The number in the bracket gives the year 
spanning the reference sequences in the cluster or branch; the number in the square bracket 
indicates the number of Nigerian sequences in the cluster or branch. The numbers labeled at 
the nodes were bootstrapping values. Country code: BE (Belgium), CM (Cameroon), CN 
(China), CU (Cuba), ES (Spain), IT (Italy), GH (Ghana), KE (Kenya), NG (Nigeria), PT 
(Portugal), and SE (Sweden).
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Further characterization of phylogenetically unresolved Nigerian sequences. The 13 
representative Nigerian unclassifiable sequences (Table 1) were further analyzed 
individually using SimPlot59 for genetic similarity (200-bp window, 20-bp step, and two-
parameter Kimura algorithm). The selection of HIV-1 reference subtypes for analysis was 
based on the genetic distance analysis (Table 2). Only three to four relevant reference 
subtypes were chosen to generate the graph to show the gene structure of query sequences 
(a). The dashed line was used to determine the relatedness of the query sequence to the 
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selected reference subtypes at the 95% similarity threshold across the gene. The segment of 
the query sequence with a length of less than 200 nucleotides and less than 95% similarity to 
the references was assigned a “U” indicating an unresolved subtyping for the sequence 
portion. The chimeric subtyping of the query sequence was given in each of the SimPlot 
diagrams (a) and populated in Table 2. To explore the recombinant events, 8 among the 13 
unclassifiable (U) sequences were again analyzed using the BootScan59 method, 
demonstrating a clear recombination event (b).
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TABLE 1
HIV-1 SUBTYPE DISTRIBUTION AMONG 271 SEQUENCES OBTAINED FROM NIGERIAN HIV-1-













Unclassifiable (U) 17 6.3
Pure subtypes 85 31.4
CRFs 186 68.6
CRF, circulating recombinant form.
The figures in bold are subtype or CRFs having higher prevalence.
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TABLE 2
CHARACTERIZATION OF 13 UNCLASSIFIABLE (U) NIGERIAN HIV-1 SEQUENCES
Sequence ID
Method used for subtypinga
Possible subtypePhylogenetic tree Genetic distance SimPlot
5186 CRF43-02G/G 0.0449/0.0593 CRF43-02G/G CRF43-02G/G
5287 CRF02-AG/CRF36-cpx 0.049/0.049 CRF36/A/CRF36 U/CRF36-cpx
5290 CRF02-AG/CRF36-cpx 0.0605/0.0521 CRF36/CRF06/CRF36 U/CRF36-cpx
5303 CRF02-AG/CRF36-cpx 0.0581/0.0572 A/C/CRF36 U/CRF36-cpx
5298 CRF02-AG/CRF36-cpx 0.0419/0.0431 A/CRF36-cpx A/CRF36-cpx
5261 CRF02-AG/CRF36-cpx 0.0498/0.0554 A/CRF02-cpx A/CRF36-cpx
5102 CRF02-AG/CRF45-cpx 0.0644/0.0675 A/K A/U
5305 CRF15-01B/CRF01-AE 0.0663/0.0764 A/CRF15-01B A/U
5089 CRF23-BG/CRF19-cpx 0.0669/0.0679 CRF36-cpx/B U/B
5343 CRF21-A2D/D/CRF19-cpx 0.0621/0.0525/0.0611 U/D U/D
5202 CRF37-cpx/CRF02-AG/G 0.741/0.0699/0.699 CRF15-01B/G CRF15-01B/G
5078 CRF36-cpx/CRF43-02G/G 0.0552/0.0598/0.0628 CRF43/CRF36/G U
5299 CRF36-cpx/CRF43-02G 0.0687/0.0691 CRF43/CRF36/G U
a
Details of methodology were described in Materials and Methods.
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TABLE 4
CHANGES OF CODON PATTERN AT POSITION 179 OF THE REVERSE TRANSCRIPTASE
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